Releases Geral
AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 23 de agosto de 2024
AiViva Biopharma
- Novel JEL Technology for Periocular Administration
COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) — AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a Phase 1 trial with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME). We have achieved a major milestone, full enrollment in our Phase 1, Safety Trial in the U.S. said Diane Tang-Liu, PhD, CEO, President & Co-Founder of AiViva Biopharma. AIV007 (lenvatinib) is a broad-spectrum tyrosine kinase inhibitor, targeting the convergence of fibrosis, angiogenesis, and inflammation. We believe AIV007, formulated with our proprietary JEL technology and administered periocularly, has the potential to address the root causes of wet AMD, DME and many other ocular diseases. We are on target to have the study completed, and full results Q1 2025.
This Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial, with 18 subjects, who have received a single periocular injection of AIV007 and will undergo monthly evaluation for up to 6 months to assess safety, tolerability, biological activity, and the reduction of treatment burden.
About Age-Related Macular Degeneration and Diabetic Macular Edema
AMD is a progressive retinal disease that is the leading cause of blindness in adults over the age of 60, affecting up to 15 million U.S. people. AMD affects the macular, center portion of the retina, that is responsible for central vision and color perception. In patients with wet AMD vision loss is caused by abnormal blood vessels leaking fluid and blood into and beneath the retina. Diabetic macular edema is manifested as retinal thickening and swelling caused by accumulation of intraretinal fluid usually due to blood sugar levels being consistently high. If untreated, chronic macular edema can lead to irreversible damage of the macula and permanent vision loss.
About AiViva Biopharma, Inc.
AiViva is a clinical stage biotech company led by a team of seasoned industry experts with proven track record in drug development and commercialization. AiViva has developed innovative approaches to address high unmet medical needs through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis. Core competencies include development of novel drugs using proprietary technologies, including JEL, in specialty therapeutic areas of ophthalmology, dermatology, urology and oncology. Please visit www.aiviva.com to learn more.
Contact:
AiViva Biopharma
office@aiviva.com
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral Turismo brasileiro arrecada R$ 162 bilhões entre 2023 e 2024
29 de julho de 2024(DINO - 29 jul, 2024) - Segundo estudo com dados compilados pela Confederação Nacional do Comércio de Bens, Serviços e Turismo (CNC), e divulgados no p
Saiba Mais -
Releases Geral FIBO e Arnold apontam tendências do setor fitness em evento
12 de abril de 2024São Paulo, SP--(DINO - 12 abr, 2024) - Na cidade de Colônia, na Alemanha, do dia 11 a 14 de abril, a FIBO Global Fitness apresenta algumas mostras com o objetivo de promover um se
Saiba Mais -
Releases Geral Crédito inteligente dá fôlego a pequenas e médias empresas
9 de abril de 2024(DINO - 09 abr, 2024) - A economia de um país não se sustenta ancorada numa indústria ou em um comércio isoladamente. É preciso que todo ecossis
Saiba Mais